Evidence map›Paper›PMID 38269243›Full record

ArticleClinical & translational immunology2024

Multi-omics integration reveals a nonlinear signature that precedes progression of lung fibrosis.

Céline Pattaroni, Christina Begka, Bailey Cardwell, Jade Jaffar, Matthew Macowan, Nicola L Harris, Glen P Westall, Benjamin J Marsland

Abstract read
In one paragraph

Article in Clinical & translational immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. From Epithelium to Therapy: Transitional Cells in Lung Fibrosis.American journal of respiratory cell and molecular biology · 2025
    Review
  7. Multi Omics Applications in Biological Systems.Current issues in molecular biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Céline PattaroniDepartment of Immunology, School of Translational Medicine Monash University Melbourne VIC Australia.ORCID https://orcid.org/0000-0002-9920-1181
Christina BegkaDepartment of Immunology, School of Translational Medicine Monash University Melbourne VIC Australia.
Bailey CardwellDepartment of Immunology, School of Translational Medicine Monash University Melbourne VIC Australia.
Jade JaffarDepartment of Immunology, School of Translational Medicine Monash University Melbourne VIC Australia.
Matthew MacowanDepartment of Immunology, School of Translational Medicine Monash University Melbourne VIC Australia.
Nicola L HarrisDepartment of Immunology, School of Translational Medicine Monash University Melbourne VIC Australia.
Glen P WestallDepartment of Immunology, School of Translational Medicine Monash University Melbourne VIC Australia.
Benjamin J MarslandDepartment of Immunology, School of Translational Medicine Monash University Melbourne VIC Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Idiopathic pulmonary fibrosis (IPF) is a devastating progressive interstitial lung disease with poor outcomes. While decades of research have shed light on pathophysiological mechanisms associated with the disease, our understanding of the early molecular events driving IPF and its progression is limited. With this study, we aimed to model the leading edge of fibrosis using a data-driven approach. Methods: Multiple omics modalities (transcriptomics, metabolomics and lipidomics) of healthy and IPF lung explants representing different stages of fibrosis were combined using an unbiased approach. Multi-Omics Factor Analysis of datasets revealed latent factors specifically linked with established fibrotic disease (Factor1) and disease progression (Factor2). Results: Features characterising Factor1 comprised well-established hallmarks of fibrotic disease such as defects in surfactant, epithelial-mesenchymal transition, extracellular matrix deposition, mitochondrial dysfunction and purine metabolism. Comparatively, Factor2 identified a signature revealing a nonlinear trajectory towards disease progression. Molecular features characterising Factor2 included genes related to transcriptional regulation of cell differentiation, ciliogenesis and a subset of lipids from the endocannabinoid class. Machine learning models, trained upon the top transcriptomics features of each factor, accurately predicted disease status and progression when tested on two independent datasets. Conclusion: This multi-omics integrative approach has revealed a unique signature which may represent the inflection point in disease progression, representing a promising avenue for the identification of therapeutic targets aimed at addressing the progressive nature of the disease.

Indexed as

disease progressionlipidomicsmetabolomicsmulti‐omicspulmonary fibrosistranscriptomics

Identifiers

PMID38269243
PMCPMC10807351

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.